Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

RELEVANT EVENT

Following Relevant Event No 252988, of 7 June 2017, Grifols informs that it has earned approval from the U.S. Food and Drug Administration (FDA) for a new product: Fibrin Sealant (Human) composed of two plasma proteins (fibrinogen and human thrombin) and indicated for surgical use in adults.

The approval from the U.S. health authorities is the culmination of an important R&D project and allows Grifols to expand its range of plasma-derived products.

Fibrin Sealant will be manufactured at the Grifols' facility located in Parets del Vallés (Barcelona, Spain).

In Barcelona, on 6 November 2017

__________________________
Nuria Martín Barnés
Secretary to the Board of Directors